Supply Agreement with SeaWith

BSF Enterprise

19/03/2026 07:00

RNS Number : 2085X

BSF Enterprise PLC

19 March 2026

 

19 March 2026

 

BSF Enterprise PLC

 

3D Bio-Tissues Limited ("3DBT")

Signs Commercial Supply Agreement with SeaWith

BSF Enterprise PLC (LSE: BSFA) (the "Company"), a leading innovator in tissue-engineered materials, is pleased to announce that its subsidiary, 3D Bio-Tissues Limited ("3DBT"), has entered into a five-year commercial Supply Agreement (the "Agreement") with SeaWith, a pioneering South Korean biotechnology company specializing in cultivated meat.

 

Strategic Partnership and Value Creation

 

The Agreement establishes a long-term commercial framework for the supply of 3DBT's proprietary City-Mix®, a premium macromolecular crowder designed to enhance cell culture efficiency. This partnership represents a significant milestone in expanding the market reach of City-Mix® into the global cultivated protein sector.

 

·      Contract Value: The total value of the Agreement to 3DBT is estimated at approximately £300,000 over the contract term.

·      Operational Integration: 3DBT will provide a regular supply of City-Mix® to support SeaWith's production pipeline for its flagship Welldone™ cultivated beef product.

·      Cost Efficiency: City-Mix® is expected to significantly lower production costs for SeaWith by reducing the requirement for expensive growth media by approximately 30%.

·      Growth Trajectory: The Agreement supports a phased scale-up of supply volumes through 2030, aligning with SeaWith's transition toward large-scale commercial production facilities.

 

About SeaWith

Founded in 2019 and headquartered in South Korea, SeaWith is a biotechnology innovator that has raised over $8 million in venture funding to date. The company utilizes seaweed-derived technologies to produce sustainable, slaughter-free meat alternatives, focusing on scalability and the reduction of environmental impact. SeaWith is a designated operator under South Korea's Gyeongbuk Cell-Cultured Food Regulatory Free Zone, reflecting the company's leadership in advancing cultivated food innovation within a government-supported regulatory framework.

 

END

 

Engage with the BSF Enterprise management team directly by asking questions, watching video
 summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
 website here:

 

https://bsfenterprise.com/link/Pqnkoy

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC
Geoff Baker - Chairman
Che Connon - CEO & Director
We encourage all investors to share questions on this announcement via our investor website.
https://bsfenterprise.com/s/a1f22b
Shard Capital (Broker)
Damon Heath
Isabella Pierre
(0)20 4530 6926
(0)20 4530 6928
ISIN of the Ordinary Shares
is GB00BHNBDQ51.
SEDOL Code is BHNBDQ5.


 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
AGRMZGMFNRDGVZM